-
Jan 17, 2025 | 
cardiab.biomedcentral.com | Institut Gustave Roussy
Recent years have seen a significant progress in understanding the pathophysiology of HFpEF, leading to the recognition of HFpEF as a multi-organ syndrome rather than an isolated disease of the heart [12]. The burden of non-cardiac comorbidities is remarkably higher in HFpEF compared to HFrEF [14]. Furthermore, patients with HFpEF are more likely to die from non-cardiovascular events than those with HFrEF [14].
-
Aug 22, 2024 | 
academic.oup.com | Institut Gustave Roussy
As the global demographic landscape continues to shift towards an aged population, so does the medical and socioeconomic burden of cardiovascular diseases. Indeed, ageing is one of, if not the, key risk factor for the development of cardiovascular diseases. However, there are currently no approved cardiovascular therapeutics that primarily target the molecular and cellular mechanisms underlying the ageing process itself.
-
Jul 29, 2024 | 
bmccancer.biomedcentral.com | Institut Gustave Roussy |Aix-Marseille Univ |Institut Paoli-Calmettes |Institut Català d’Oncologia
Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.
-
Jul 21, 2024 | 
bmccancer.biomedcentral.com | Institut Gustave Roussy |Aix-Marseille Univ |Institut Paoli-Calmettes |Institut Català d’Oncologia
ENDOLUNG was an open-label phase 1/2 study of the combination of ABTL0812 plus CP in advanced or recurrent EC patients (the phase 1 also included patients with sq-NSCLC). Patients were recruited in 9 academic institutions, located in Spain and France, from November 2016 to February 2020. This study was registered with EudraCT number 2016-001352-21 and at ClinicalTrials.gov with identifier NCT03366480. During the phase 1, patients were recruited only in 6 academic institutions from Spain.
-
Jun 4, 2024 | 
inria.hal.science | Liwei Zhao |Institut Gustave Roussy |Zhe Shen |Guido Kroemer
Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma Mots clés Immunotherapy danger associated molecular pattern autophagy phagocytosis Domaines Cancer Immunothérapie Hématologie Fichier principal Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma.pdf (984.15 Ko) Télécharger le fichier Origine Fichiers éditeurs autorisés sur une archive ouverte...
-
May 9, 2024 | 
jamanetwork.com | Maha Hussain |Institut Gustave Roussy |Neal Shore
Abstract
Importance
Metastatic hormone-sensitive prostate cancer is currently an incurable disease. Despite a high response rate to androgen-deprivation therapy, most cases progress to castration-resistant disease, the terminal phase. This review provides a summary of the most recent evidence for current and emerging management strategies, including treatment intensification with combinations of therapies.
-
Apr 10, 2024 | 
inria.hal.science | Thomas Kaley |Mehdi Touat |Institut Gustave Roussy |Vivek Subbiah
Article Dans Une Revue Journal of Clinical Oncology Année : 2018 BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study Fichier principal kaley-et-al-2018-braf-inhibition-in-brafv600-mutant-gliomas-results-from-the-ve-basket-study.pdf (793.05 Ko) Télécharger le fichier Origine : Publication financée par une institution Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification hal-04541090 , version 1 (10-04-2024) Thomas Kaley, Mehdi Touat,...
-
Mar 13, 2024 | 
aacrjournals.org | Institut Gustave Roussy
This content is only available via PDF.
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
-
Feb 28, 2024 | 
hal.science | Ingo K. Mellinghoff |Benjamin M. Ellingson |Mehdi Touat |Institut Gustave Roussy
Article Dans Une Revue Journal of Clinical Oncology Année : 2020 Ivosidenib in Isocitrate Dehydrogenase 1 – Mutated Advanced Glioma Fichier principal mellinghoff-et-al-2020-ivosidenib-in-isocitrate-dehydrogenase-1-mutated-advanced-glioma.pdf (1019.09 Ko) Télécharger le fichier Origine : Fichiers éditeurs autorisés sur une archive ouverte Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification hal-04481741 , version 1 (28-02-2024) Ingo K Mellinghoff, Benjamin M...
-
Feb 6, 2024 | 
aacrjournals.org | Institut Gustave Roussy |Jose Luis |South San Francisco |Bristol Myers Squibb
Purpose: The immunocytokine cergutuzumab amunaleukin (CEA-IL2v) showed manageable safety and favorable pharmacodynamics in Phase I/Ib trials in patients with advanced/metastatic carcinoembryonic antigen-positive (CEA+) solid tumors, but this was accompanied by a high incidence of anti-drug antibodies (ADAs). We examined B-cell depletion with obinutuzumab as a potential mitigation strategy.
